TRI-NORINYL 28-DAY Drug Patent Profile

When do Tri-norinyl 28-day patents expire, and what generic alternatives are available?

Tri-norinyl 28-day is a drug marketed by Dr Reddys Labs Sa and is included in one NDA.

The generic ingredient in TRI-NORINYL 28-DAY is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.

Summary for TRI-NORINYL 28-DAY

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	6
Patent Applications:	214
DailyMed Link:	TRI-NORINYL 28-DAY at DailyMed

US Patents and Regulatory Information for TRI-NORINYL 28-DAY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Sa	TRI-NORINYL 28-DAY	ethinyl estradiol; norethindrone	TABLET;ORAL-28	018977-002	Apr 13, 1984	AB	RX	Yes	Yes

Expired US Patents for TRI-NORINYL 28-DAY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Dr Reddys Labs Sa	TRI-NORINYL 28-DAY	ethinyl estradiol; norethindrone	TABLET;ORAL-28	018977-002	Apr 13, 1984

International Patents for TRI-NORINYL 28-DAY

See the table below for patents covering TRI-NORINYL 28-DAY around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	26087	METHOD OF CONTRACEPTION AND PHARMACEUTICAL PACKAGE THEREFOR
Australia	560922
Malaysia	8700596	METHOD OF CONTRACEPTION AND PHARMACEUTICAL PACKAGE THEREFOR
New Zealand	201539	PROCESS FOR THE PRODUCTION OF A CONTRACEPTIVE COMPOSITION
Germany	3229612
United Kingdom	2104779	METHOD OF CONTRACEPTION AND PHARMACEUTICAL PACKAGE THEREFOR

Supplementary Protection Certificates for TRI-NORINYL 28-DAY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
1453521	300814	Netherlands		PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1380301	CA 2009 00017	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629

Market Dynamics and Financial Trajectory for TRI-NORINYL 28-DAY

Last updated: February 2, 2026

Executive Summary

TRI-NORINYL 28-DAY is a combined oral contraceptive (COC) containing a distinct formulation of norethindrone and other progestins, marketed primarily for women seeking long-term family planning options. As of 2023, the contraceptive market is experiencing significant growth driven by demographic shifts, increasing awareness of reproductive health, and expanding healthcare infrastructure globally. This report examines the market dynamics influencing TRI-NORINYL 28-DAY, evaluates the product’s financial trajectory, and provides strategic insights for manufacturers and investors.

---

What is TRI-NORINYL 28-DAY?

Attribute	Details
Drug Type	Oral contraceptive (Combined)
Dosage Form	28-day blister pack
Active Ingredients	Norethindrone, Ethinyl Estradiol (or other progestins)
Indications	Contraception, hormonal regulation
FDA Status	Approved in multiple jurisdictions

Note: While "TRI-NORINYL" is proprietary, similar formulations are widely used, indicating potential market overlap.

---

What Are the Key Market Drivers?

Driver	Impact	Sources
Rising global contraceptive awareness	Increases demand, especially in emerging markets	[1], [2]
Growing female workforce participation	Boosts long-term family planning choices	[3]
Expanding healthcare infrastructure in emerging economies	Facilitates better access to contraceptives	[4]
Regulatory approvals and label expansions	Broaden market eligibility	[5]
Innovation in formulations (multipurpose products)	Enhances adherence and patient compliance	[6]

Market Segments

• Geographic: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
• User Type: Women aged 15-49, family planning clinics, hospitals
• Distribution Channels: Retail pharmacies, hospitals, online pharmacies, health clinics

---

How Is the Market Shaping Up?

Current Market Size and Forecast

Year	Global Market Size (USD billions)	CAGR (2023-2030)	Key Notes
2023	10.2	4.8%	Steady growth, mature segments
2025	11.4		Expansion in emerging markets
2030	15.0	5.5%	Increased market penetration

Sources: Transparency Market Research [1], GlobalData [2]

Regional Trends

Region	Market Size (USD billions)	CAGR (2023-2030)	Drivers
North America	3.4	3.2%	High contraceptive penetration, insurance coverage
Europe	2.5	3.5%	Regulatory support, high healthcare expenditure
Asia-Pacific	2.9	6.2%	Population growth, improving healthcare access
Latin America	1.2	4.0%	Rising awareness, urbanization
Middle East & Africa	0.2	7.4%	Market expansion, increased funding for health

Competitive Landscape

Key Players	Market Share (%)	Product Portfolio Focus	Recent Initiatives
Bayer AG (Yaz, Yasmin)	35%	Combination contraceptives, generics	New formulations, digital health apps
Pfizer Inc.	20%	Multipurpose pills, injectables	Regulatory approvals for new drugs
Teva Pharmaceutical Industries Ltd	15%	Generic contraceptives	Market entry strategies
Others	30%	Various regional and local brands	Local partnerships, licensing

---

What Are the Future Financial Trajectories?

Revenue Streams and Growth Opportunities

• Brand loyalty and patent protections enhance revenue stability.
• Expanding indications (e.g., menstrual regulation, hormone therapy) open new markets.
• Biosimilars and generics challenge branded products but also introduce volume growth opportunities.

Market Challenges

• Pricing pressures due to commoditization and generics.
• Regulatory hurdles vary across regions, impacting market entry timelines.
• Supply chain disruptions influence product availability and costs.

Forecasted Financials (2023–2030)

Year	Estimated Revenue (USD billions)	CAGR	Comments
2023	10.2	--	Market base
2025	11.4	4.8%	Early adoption in emerging economies
2027	13.5	6.0%	Product line expansions, new regulations
2030	15.0	5.5%	Maturation, increased penetration globally

---

How Do Regulatory Policies Impact Market Dynamics?

Region	Regulatory Framework	Notable Policies	Impact on Market
North America	FDA regulatory pathways	Approved for various indications, fast-track options	Accelerates product availability
European Union	EMA standards	Reinforces safety, facilitates cross-border marketing	Ease of market expansion
Asia-Pacific	Varies (stringent to permissive)	Approvals growing, local registration processes	Faster approvals, market entry barriers
Latin America & Africa	Emerging regulatory infrastructure	Increasing adoption, regional guidelines evolving	Opportunities for early entry

---

What Are the Key Comparative Analyses?

Aspect	TRI-NORINYL 28-DAY	Competitors (e.g., Yaz, Microgynon)	Differentiators
Formulation	Norethindrone-based, 28-day cycle	Ethinyl estradiol + drospirenone, others	Unique hormone combinations
Efficacy Rate	>99% with consistent use	Similar or marginally higher	Cost, side effect profile
Side Effect Profile	Menstrual irregularities, nausea	Varies, often similar	Tolerance, adverse events profile
Price Point	Mid-range	Competitive, often premium	Affordability and accessibility
Regulatory Approval	Approved in multiple markets	Varies, some region-specific	Regulatory track record

---

What Are Critical Strategic Considerations?

Area	Consideration
Patent & Exclusivity	Patent expiration timelines impact profitability
Launch Strategies	Direct-to-consumer marketing, physician outreach
Partnership Opportunities	Licensing, co-marketing with regional players
Research & Development	Innovations in delivery (e.g., patches, rings)
Market Penetration	Focus on underpenetrated markets, demographic targeting

---

FAQs

1. What factors are likely to influence the market share of TRI-NORINYL 28-DAY?

Regulatory approvals, pricing strategies, physician prescribing behaviors, patient preferences, and competition from generics.

2. How significant is the impact of patent expiry on TRI-NORINYL's market trajectory?

Patent expiry typically diminishes exclusivity, leading to increased generic competition, pressure on prices, and potential decline in revenue unless offset by formulation improvements or new indications.

3. Are there emerging markets with higher growth potential for TRI-NORINYL?

Yes, Asia-Pacific regions like India and China exhibit high CAGR due to expanding healthcare access and growing awareness. Latin America and parts of Africa are also emerging markets.

4. How do regulatory differences influence the time to market for TRI-NORINYL in different regions?

Stringent regulatory environments can extend approval timelines, requiring localized clinical trials and compliance measures. Conversely, regions with streamlined processes facilitate faster market entry.

5. What role does innovation play in maintaining TRI-NORINYL’s market position?

Developing multipurpose or extended-cycle formulations, improving tolerability, or integrating digital health support can sustain competitiveness amid generic proliferation.

---

Key Takeaways

• The global contraceptive market is projected to grow at a CAGR of approximately 5% through 2030, driven by demographic shifts and increased health awareness.
• TRI-NORINYL 28-DAY benefits from high efficacy, established regulatory approval, and the potential for expansion into emerging markets.
• Competitive differentiation hinges on pricing, formulation innovations, and successful regional regulatory strategies.
• Patent expiry timelines and regulatory landscapes are critical factors influencing future revenues.
• Strategic partnerships and R&D investments are pivotal in fortifying market position amid increasing generic competition.

---

References

[1] Transparency Market Research, "Contraceptive Drugs Market," 2022.
[2] GlobalData, "Reproductive Health Market Analysis," 2023.
[3] World Bank, "Women in the Workforce," 2022.
[4] WHO, "Global Health Infrastructure Reports," 2022.
[5] U.S. FDA, "Contraceptive Approvals," 2023.
[6] IMS Health, "Innovation Trends in Contraceptive Delivery," 2022.